Bioven is under clinical development by Biopharma Plasma and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to GlobalData, Phase III drugs for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bioven’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bioven is under development for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia caused by the severe acute coronavirus 2 (SARS-COV2) and chronic primary immune thrombocytopenia. The drug candidate comprises of immunoglobulin-G donated from the plasma cells of patients. It is administered through intravenous route.
Biopharma Plasma overview
Biopharma Plasma is a biopharma immunobiological pharmaceutical company that develops and produces human plasma-derived medicines for the treatment of oncological diseases. Biopharma Plasma is headquartered in Kyiv, Ukraine.
For a complete picture of Bioven’s drug-specific PTSR and LoA scores, buy the report here.